News
09-26-2011, 02:11 AM
The first randomised trial to investigate the use of trastuzumab emtansine (T-DM1) - an antibody-guided drug - for the initial treatment of HER2- (human epidermal growth factor receptor-2) positive metastatic breast cancer has shown that it makes a significant difference to the time women live without their disease worsening...
More... (http://www.medicalnewstoday.com/releases/234970.php)
More... (http://www.medicalnewstoday.com/releases/234970.php)